Patents by Inventor Klaus WENING
Klaus WENING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210046009Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.Type: ApplicationFiled: November 2, 2020Publication date: February 18, 2021Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, SEBASTIAN SCHWIER, ULRIKE BERTRAM
-
Patent number: 10842750Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.Type: GrantFiled: September 9, 2016Date of Patent: November 24, 2020Assignee: GRÜNENTHAL GMBHInventors: Klaus Wening, Sebastian Schwier, Ulrike Bertram
-
Publication number: 20200338069Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than. 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: July 14, 2020Publication date: October 29, 2020Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20200276188Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: May 11, 2020Publication date: September 3, 2020Applicant: Grünenthal GMBHInventors: KLAUS WENING, ANJA GEIßLER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20200268748Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: May 11, 2020Publication date: August 27, 2020Applicant: GRUNENTHAL GMBHInventors: Klaus WENING, ANJA GEISSLER-FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20200197327Abstract: The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.Type: ApplicationFiled: March 5, 2020Publication date: June 25, 2020Applicant: GRÜNENTHAL GMBHInventors: Klaus WENING, Lutz Barnscheid, Sebastian Schwier, Anja Geibler
-
Patent number: 10624862Abstract: The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.Type: GrantFiled: July 10, 2014Date of Patent: April 21, 2020Assignee: GRÜNENTHAL GMBHInventors: Klaus Wening, Lutz Barnscheid, Sebastian Schwier, Anja Geißler
-
Publication number: 20200030317Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur. The tamper-resistant pharmaceutical dosage form is useful in methods of treat diseases or disorders susceptible to the pharmacologically active compound; and in some embodiments discourages abuse in that when reduced to a powder the powdered dosage form exhibits a lower score for drug-liking than the pharmacologically active compound itself as assessed on a visual analog scale.Type: ApplicationFiled: September 27, 2019Publication date: January 30, 2020Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20200009055Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: July 19, 2019Publication date: January 9, 2020Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEISSLER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20190247332Abstract: A pharmaceutical dosage form is disclosed having a breaking strength of at least 300 N and comprising (i) an ephedrine component selected from the group consisting of ephedrine, pseudoephedrine and the physiologically acceptable salts thereof, wherein preferably the weight content of the ephedrine component is within the range of from 0.1 to 60 wt.-%, relative to the total weight of the pharmaceutical dosage form; and (ii) a physiologically acceptable conversion inhibitor that is capable of inhibiting the chemical conversion ex vivo of the ephedrine component into methamphetamine. Also disclosed is a method of treating a disease, disorder or condition, preferably selected from the group consisting of tissue hyperemia, edema, and nasal congestion, comprising the administration of the pharmaceutical dosage form to a subject in need thereof.Type: ApplicationFiled: February 8, 2019Publication date: August 15, 2019Applicant: Grünenthal GmbHInventors: Isabell IMMOHR, Peter PERSICH, Alexander WESQUET, Carmen STOMBERG, Klaus WENING, Sebastian SCHWIER
-
Patent number: 10335373Abstract: A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.Type: GrantFiled: April 17, 2013Date of Patent: July 2, 2019Assignee: GRUNENTHAL GMBHInventors: Klaus Wening, Lutz Barnscheid, Sebastian Schwier
-
Publication number: 20190142757Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.Type: ApplicationFiled: November 9, 2018Publication date: May 16, 2019Applicant: GRÜNENTHAL GMBHInventors: LUTZ BARNSCHEID, ANJA GEIßLER, KLAUS WENING, JANA PÄTZ
-
Publication number: 20190133956Abstract: The invention relates to a reinforced pharmaceutical dosage form comprising a pharmacologically active ingredient and fibers. The reinforced pharmaceutical dosage form is tamper-resistant and thus useful for the avoidance of drug abuse or misuse. The invention also relates to the preparation of such dosage forms and their use in therapy.Type: ApplicationFiled: January 7, 2019Publication date: May 9, 2019Applicant: GRÜNENTHAL GMBHInventors: Marcel HAUPTS, Klaus WENING, Carmen STOMBERG, Siegfried EBNER
-
Publication number: 20190111050Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: December 12, 2018Publication date: April 18, 2019Applicant: GRÜNENTHAL GMBHInventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
-
Publication number: 20190110992Abstract: The invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of said pharmacologically active compound is contained in a multitude of immediate release particles providing immediate release of the pharmacologically active compound; wherein another portion of said pharmacologically active compound is contained in at least one controlled release particle providing controlled release of the pharmacologically active compound; and wherein the breaking strength of each of the immediate release particles and/or of the at least one controlled release particle is at least 300 N.Type: ApplicationFiled: October 12, 2018Publication date: April 18, 2019Applicant: Grünenthal GmbHInventors: Carmen Stomberg, Harald Paul, Klaus Wening, Sebastian Schwier
-
Publication number: 20190054081Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: October 22, 2018Publication date: February 21, 2019Applicant: GRÜNENTHAL GMBHInventors: Klaus Wening, Anja Geissler-Fichtner, Jana Denker, Lutz Barnscheid
-
Publication number: 20190015343Abstract: The invention relates to a three-dimensionally printed pharmaceutical dosage form comprising a first pharmacologically active ingredient and a second pharmacologically active ingredient; wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient in the pharmaceutical dosage form is within the range of from 10,000:1 to 1:1. The invention also relates to a process for the preparation of such pharmaceutical dosage form by three-dimensional printing, preferably by fused deposition modeling.Type: ApplicationFiled: September 18, 2018Publication date: January 17, 2019Applicant: GRÜNENTHAL GMBHInventors: Carmen STOMBERG, Klaus WENING, Marcel HAUPTS
-
Publication number: 20190015344Abstract: The invention relates to a pharmaceutical dosage form having a density below the density of gastric fluid, wherein the dosage form comprises a pharmacologically active ingredient and a cavity. The invention also relates to a process for the preparation of said dosage form comprising a three-dimensional printing step.Type: ApplicationFiled: September 18, 2018Publication date: January 17, 2019Applicant: GRÜNENTHAL GMBHInventors: Klaus WENING, Carmen STOMBERG, Marcel HAUPTS
-
Publication number: 20180369237Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.Type: ApplicationFiled: August 29, 2018Publication date: December 27, 2018Applicant: GRÜNENTHAL GMBHInventors: Klaus WENING, ANJA GEIßLER, JANA DENKER, LUTZ BARNSCHEID
-
Patent number: 10154966Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.Type: GrantFiled: May 27, 2014Date of Patent: December 18, 2018Assignee: GRÜNENTHAL GMBHInventors: Lutz Barnscheid, Anja Geiβler, Klaus Wening, Jana Pätz